Shan Li

Shan Li

Auto-generated profile, based on publicly available information

Shan Li

Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZMZhijiang Miao
Zhijiang Miao
SZShaoshi Zhang
Shaoshi Zhang
XOXumin Ou
Xumin Ou
SLShan Li
Shan Li
ZMZhongren Ma
Zhongren Ma
QPQiuwei Pan
Qiuwei Pan
Background: Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure. We aim to establish the global epidemiology, infection mode-stratified disease progression, and clinical outcome of HDV infection. Methods: We conducted a meta-analysis with a random-effects model and performed data synthesis. Results: The pooled prevalence of HDV is 0.80% (95% confidence interval [CI], 0.63–1.00) among the general population and 13.02% (95% CI, 11.96–14.11) among HBV carriers, corresponding to 48–60 million infections globally. Among HBV patients with fulminant hepatitis, cirrhosis, or hepatocellular carcinoma, HDV prevalence is 26.75% (95% CI, 19.84–34.29), 25.77% (95% CI, 20.62–31.27), and 19.80% (95% CI, 10.97–30.45), respectively. The odds ratio (OR) of HDV infection among HBV patients with chronic liver disease compared with asymptomatic controls is 4.55 (95% CI, 3.65–5.67). Hepatitis delta virus-coinfected patients are more likely to develop cirrhosis than HBV-monoinfected patients with OR of 3.84 (95% CI, 1.79–8.24). Overall, HDV infection progresses to cirrhosis within 5 years and to hepatocellular carcinoma within 10 years, on average. Conclusions: Findings suggest that HDV poses a heavy global burden with rapid progression to severe liver diseases, urging effective strategies for screening, prevention, and treatment.

1 January 2017 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
SLShan Li
Shan Li
SKSergey R. Konstantinov
Sergey R. Konstantinov
RSRon Smits
Ron Smits
Maikel PeppelenboschMaikel Peppelenbosch
Maikel Peppelenbosch

23 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
WCWanlu Cao
Wanlu Cao
MLMeng Li
Meng Li
JLJiaye Liu
Jiaye Liu
SZShaoshi Zhang
Shaoshi Zhang
LNLisanne Noordam
Lisanne Noordam
QPQiuwei Pan
Qiuwei Pan
Cancer stem cells (CSCs) or tumor-initiating cells (TICs) are thought to be the main drivers for disease progression and treatment resistance across various cancer types. Identifying and targeting these rare cancer cells, however, remains challenging with respect to therapeutic benefit. Here, we report the enrichment of LGR5 expressing cells, a well-recognized stem cell marker, in mouse liver tumors, and the upregulation of LGR5 expression in human hepatocellular carcinoma. Isolated LGR5 expressing cells from mouse liver tumors are superior in initiating organoids and forming tumors upon engraftment, featuring candidate TICs. These cells are resistant to conventional treatment including sorafenib and 5-FU. Importantly, LGR5 lineage ablation significantly inhibits organoid initiation and tumor growth. The combination of LGR5 ablation with 5-FU, but not sorafenib, further augments the therapeutic efficacy in vivo. Thus, we have identified the LGR5+ compartment as an important TIC population, representing a viable therapeutic target for combating liver cancer.

9 November 2017 in Microbiome
Verified
Journal Article
Open access
PDF file
SLShan Li
Shan Li
GFGwenny M. Fuhler
Gwenny M. Fuhler
NBNahush Bn
Nahush Bn
TJTony Jose
Tony Jose
MBMarco J. Bruno
Marco J. Bruno
SKSergey R. Konstantinov
Sergey R. Konstantinov
It is clear that specific intestinal bacteria are involved in the development of different premalignant conditions along the gastrointestinal tract. An analysis of the microbial constituents in the context of pancreatic cystic lesions has, however, as yet not been performed. This consideration prompted us to explore whether endoscopically obtained pancreatic cyst fluids (PCF) contain bacterial DNA and to determine the genera of bacteria present in such material. Total DNA was isolated from 69 PCF samples. Bacterial 16S rRNA gene-specific PCR was performed followed by Sanger sequencing and de novo deep sequencing for the V3-V4 variable region of 16S rRNA gene. We observed that 98.2% of the samples were positive in conventional PCR, and that 100% of selected PCF samples (n = 33) were positive for bacterial microbiota as determined by next generation sequencing (NGS). Comprehensive NGS data analysis of PCF showed the presence of 408 genera of bacteria, of which 17 bacterial genera were uniquely abundant to PCF, when compared to the Human Microbiome Project (HMP) database and 15 bacterial microbiota were uniquely abundant in HMP only. Bacteroides spp., Escherichia/Shigella spp., and Acidaminococcus spp. which were predominant in PCF, while also a substantial Staphylococcus spp. and Fusobacterium spp. component was detected. These results reveal and characterize an apparently specific bacterial ecosystem in pancreatic cyst fluid samples and may reflect the local microbiota in the pancreas. Some taxa with potential deleterious functions are present in the bacterial abundance profiles, suggesting that the unique microbiome in this specific niche may contribute to neoplastic processes in the pancreas. Further studies are needed to explore the intricate relationship between pathophysiological status in the host pancreas and its microbiota.

26 February 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
SLShan Li
Shan Li
MLMarla Lavrijsen
Marla Lavrijsen
ABAron Bakker
Aron Bakker
Marcin MagierowskiMarcin Magierowski
Marcin Magierowski
KMKatarzyna Magierowska
Katarzyna Magierowska
RSRon Smits
Ron Smits

19 December 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
TTTao Tan
Tao Tan
DMDmitri Mouradov
Dmitri Mouradov
MLMargaret Lee
Margaret Lee
GGGrace Gard
Grace Gard
YHYumiko Hirokawa
Yumiko Hirokawa
Oliver SieberOliver Sieber
Oliver Sieber
Predictive drug testing of patient-derived tumor organoids (PDTOs) holds promise for personalizing treatment of metastatic colorectal cancer (mCRC), but prospective data are limited to chemotherapy regimens with conflicting results. We describe a unified framework for PDTO-based predictive testing across standard-of-care chemotherapy and biologic and targeted therapy options. In an Australian community cohort, PDTO predictions based on treatment-naive patients (n = 56) and response rates from first-line mCRC clinical trials achieve 83% accuracy for forecasting responses in patients receiving palliative treatments (18 patients, 29 treatments). Similar assay accuracy is achieved in a prospective study of third-line or later mCRC treatment, AGITG FORECAST-1 (n = 30 patients). "Resistant" predictions are associated with inferior progression-free survival; misclassification rates are similar by regimen. Liver metastases are the optimal site for sampling, with testing achievable within 7 weeks for 68.8% cases. Our findings indicate that PDTO drug panel testing can provide predictive information for multifarious standard-of-care therapies for mCRC.